proteas
play
import
role
activ
precursor
protein
matur
form
recycl
protein
essenti
function
bodi
vide
infra
classifi
famili
base
evolutionari
relationship
major
proteas
class
base
catalyt
type
includ
serin
cystein
aspart
threonin
glutam
acid
metalloproteas
proteas
recogn
specif
sequenc
amino
acid
substrat
cleav
peptid
bond
residu
figur
via
nucleophil
attack
side
chain
cystein
serin
threonin
residu
water
molecul
aspart
glutam
acid
metalloproteas
amid
carbon
scissil
bond
approxim
proteas
genom
encod
human
genom
involv
plethora
import
physiolog
process
includ
protein
turnov
digest
blood
coagul
wound
heal
fertil
cell
differenti
growth
cell
signal
immun
respons
apoptosi
howev
uncontrol
poorli
regul
undesir
proteolysi
lead
variou
diseas
exampl
includ
cancer
metastasi
angiogenesi
proteasom
matrix
metalloproteinas
mmp
caspas
furin
neurolog
diseas
alzheim
diseas
parkinson
diseas
ischemia
central
nerv
system
injuri
disintegrin
metalloproteinas
domaincontain
protein
inflamm
arthriti
chronic
obstruct
pulmonari
diseas
copd
asthma
crohn
diseas
inflammatori
bowel
diseas
coliti
diverticul
chronic
liver
diseas
mmp
cathepsin
neutrophil
elastas
blood
coagul
thrombin
factor
xa
diabet
dipeptidyl
peptidas
cardiovascular
diseas
atherosclerosi
hypertens
cardiomyopathi
congest
heart
failur
myocardi
infarct
neovascular
cardiac
remodel
cardiac
fibrosi
aneur
ischemiareperfus
injuri
angiotensin
convert
enzym
renin
mmp
chymas
neprilysin
calpain
osteoporosi
cathepsin
k
autoimmun
diseas
multipl
sclerosi
lupu
guillainbarr
syndrom
psoriasi
activ
protein
c
kallikrein
age
skin
mmp
neutrophil
elastas
sinc
poorlyregul
proteas
detriment
physiolog
proteas
inhibitor
bodi
help
maintain
inhibitor
balanc
control
aberr
proteas
activ
wellknown
physiolog
proteas
inhibitor
includ
serpin
superfamili
consist
antithrombin
plasminogen
activ
neuroserpin
thu
natur
synthet
proteas
inhibitor
studi
develop
variou
patholog
condit
sever
fdaapprov
drug
market
current
commerci
avail
synthet
proteas
inhibitor
target
host
proteas
includ
thrombin
factor
xa
inhibitor
coagul
dabigatran
rivaroxaban
angiotensin
convert
enzym
ace
inhibitor
hypertens
lisinopril
inhibitor
diabet
sitagliptin
proteasom
inhibitor
multipl
myeloma
bortezomib
figur
certain
virus
also
encod
viral
proteas
success
infect
host
hiv
aspart
hepat
c
viru
hcv
serin
proteas
among
wellstudi
due
signific
public
health
success
antivir
drug
develop
hiv
particl
two
copi
positivesens
singlestrand
rna
genom
upon
infect
host
cell
genom
transcrib
doublestrand
dna
revers
transcript
integr
human
genom
viru
util
host
cell
machineri
replic
produc
viru
particl
virus
releas
host
cell
undergo
matur
viral
structur
polyprotein
cleav
viral
proteas
produc
infecti
viru
particl
function
hiv
proteas
form
two
ident
monom
amino
acid
proteas
monom
contribut
one
catalyt
aspart
acid
asp
activ
site
figur
two
conserv
catalyt
residu
work
togeth
process
gag
gagpol
polyprotein
viral
matur
new
viru
particl
releas
cell
membran
activ
site
cover
two
flexibl
flap
figur
open
allow
substrat
enter
activ
site
proteas
cleav
gag
gagpol
polyprotein
precursor
nine
process
site
produc
matur
protein
figur
gener
hydrophob
amino
acid
requir
effici
cleavag
proteas
cleavag
rate
vari
significantli
base
sequenc
region
sinc
matur
viral
proteas
essenti
produc
infecti
viru
particl
proteas
target
extens
drug
discoveri
develop
effort
least
ten
hiv
proteas
inhibitor
approv
fda
includ
saquinavir
indinavir
ritonavir
nelfinavir
amprenavir
fosamprenavir
lopinavir
atazanavir
tipranavir
darunavir
figur
compound
peptidomimet
inhibitor
target
activ
site
except
tipranavir
bind
flap
region
viral
proteas
strategi
employ
target
viral
proteas
activ
site
util
reduc
small
peptid
compound
peptidyl
residu
contain
hydrophob
residu
posit
isoster
replac
scissil
bond
mimic
tetrahedr
transit
state
proteolyt
reaction
commerci
avail
drug
use
nonhydrolyz
hydroxyethylen
hydroxyethylamin
moieti
basic
core
figur
exampl
noncleav
transitionst
isoster
statin
norstatin
phosphin
reduc
amid
dihydroxyethylen
amid
recent
siliconbas
inhibitor
effect
concentr
valu
commerci
avail
inhibitor
cell
cultur
rang
nm
figur
enhanc
physicochem
pk
properti
proteas
inhibitor
prodrug
approach
also
util
exampl
fosamprenavir
phosphat
ester
prodrug
amprenavir
contain
hydrolyz
ester
bond
phosphat
prodrug
display
improv
cellular
absorpt
diminish
side
effect
addit
proteas
inhibitor
use
combin
antiretrovir
therapi
cart
regim
hcv
singl
strand
positivesens
rna
viru
genom
approxim
kb
translat
polyprotein
amino
acid
residu
least
six
distinct
hcv
genotyp
genotyp
account
approxim
hcv
infect
us
polyprotein
process
cellular
viral
proteas
gener
least
matur
structur
nonstructur
protein
hcv
encod
autoproteas
serin
proteas
proteas
autocleav
junction
serin
proteas
respons
cleavag
four
junction
viral
polyprotein
junction
well
cellular
protein
involv
innat
immun
compris
proteas
ntermin
aa
helicas
domain
ctermin
form
heterodim
protein
bind
ntermin
region
act
cofactor
proteas
enhanc
cleavag
form
trypsinlik
fold
two
contain
catalyt
triad
residu
activ
site
figur
cleavag
site
proteas
polyprotein
list
figur
residu
accommod
pocket
proteas
residu
flank
pocket
import
determin
substrat
recognit
pocket
proteas
prefer
small
hydrophob
residu
cystein
posit
substrat
hcv
known
shallow
bind
pocket
requir
extend
subtrat
span
amino
acid
residu
effici
enzym
activ
consensu
sequenc
de
xxxx
ct
transcleavag
site
x
amino
acid
commerci
avail
hcv
proteas
inhibitor
includ
telaprevir
incivek
boceprevir
victr
simeprevir
grazoprevir
voxilaprevir
paritaprevir
glecaprevir
figur
inhibitor
often
use
part
combin
therapi
inhibitor
polymeras
inhibitor
macrocycl
compound
shown
figur
display
significantli
improv
valu
telaprevir
boceprevir
firstgener
proteas
inhibitor
figur
boceptrevir
telatrevir
contain
warhead
small
residu
posit
pro
pro
surrog
posit
figur
structureact
relationship
sar
studi
hcv
proteas
inhibitor
demonstr
prefer
residu
small
hydrophob
side
chain
ethyl
propyl
trifluoroethyl
posit
bulki
substitu
posit
increas
effic
sar
studi
util
differ
warhead
group
proteas
inhibitor
shown
warhead
prefer
result
improv
bind
affin
aldehyd
counterpart
warhead
trifluoromethyl
chloromethyl
keton
found
less
effect
valu
proteas
inhibitor
rang
nm
telatrevir
boceprevir
nm
macrocycl
compound
hcv
replicon
harbor
cell
depend
viru
genotyp
use
figur
gener
strategi
employ
design
noroviru
inhibitor
involv
construct
transitionst
ts
inhibitor
ts
mimic
figur
synthes
dipeptidyl
tripeptidyl
compound
contain
glutamin
surrog
posit
numer
variat
andor
posit
efficaci
inhibitor
evalu
use
noroviru
gi
norwalk
viru
nv
gii
gv
murin
well
cellbas
assay
nv
replicon
harbor
cell
antivir
effect
inhibitor
also
evalu
use
felin
caliciviru
cell
cultur
assess
abil
inhibit
divers
norovirus
calicivirus
inclus
glutamin
surrog
posit
found
us
other
crucial
effici
inhibitori
activ
array
warhead
reactiv
residu
interact
catalyt
employ
synthesi
inhibitor
includ
aldehyd
nitril
moieti
moreov
ts
mimic
also
investig
synthes
inhibitor
examin
inhibitori
activ
fluoresc
reson
energi
transfer
fret
proteas
assay
use
noroviru
gi
gii
strain
nv
replicon
harbor
cell
cell
studi
show
although
warhead
activ
noroviru
aldehyd
warhead
display
superior
activ
fold
compar
warhead
high
chemic
reactiv
aldehyd
warhead
employ
design
ts
inhibitor
occasion
associ
lack
select
well
offtarget
effect
therefor
latent
aldehyd
warhead
aldehyd
bisulfit
adduct
revert
precursor
aldehyd
physiolog
condit
util
pharmacolog
activ
bisulfit
adduct
peptidyl
aldehyd
shown
compar
precursor
aldehyd
crystal
structur
nv
complex
dipeptidyl
inhibitor
includ
reveal
larg
conform
chang
occur
nearbi
activ
site
loop
accommod
inhibitor
bind
structur
serv
guid
develop
potent
dipeptidyl
inhibitor
use
start
point
optim
accommod
pocket
accommod
pocket
conduct
figur
fret
assay
use
gi
gii
norovirus
cell
base
assay
use
nv
replicon
harbor
cell
reveal
replac
leu
cyclohexylalanin
cha
increas
potenc
significantli
nm
nm
nm
nm
figur
substitut
mcl
substitu
increas
potenc
nm
nm
cocryst
structur
compound
reveal
structur
determin
respons
increas
potenc
figur
extens
hydrogen
bond
network
present
rel
cyclohexyl
ring
posit
tightli
optim
fill
hydrophob
subsit
nv
pro
mchlorophenyl
ring
occupi
hydrophob
pocket
near
valu
also
found
well
correl
valu
nv
replicon
harbor
cell
cell
respect
addit
sar
studi
perform
probe
hydrophob
pocket
noroviru
exploit
favor
hydrophob
bind
interact
specif
mcl
benzyl
moieti
project
toward
subsit
proteas
figur
close
proxim
string
hydrophob
amino
acid
exploit
appropri
cap
modif
includ
use
sulfonamid
lipid
moieti
synthes
compound
display
high
potenc
inhibit
noroviru
replic
cell
replic
nv
harbor
cell
increas
potenc
prodrug
approach
highli
success
improv
absorpt
distribut
metabol
excret
adm
pk
characterist
hiv
hcv
proteas
inhibitor
group
util
aldehyd
bisulfit
adduct
inhibitor
synthes
ester
carbam
prodrug
improv
pk
pharmacodynam
pd
properti
gener
prodrug
found
compar
efficaci
precursor
exhibit
lower
low
cytotox
increas
stabil
liver
microsom
reduc
plasma
protein
bind
demonstr
sound
prodrug
approach
develop
nv
therapeut
well
gener
applic
viral
serin
cystein
proteas
medic
relev
dipeptidyl
inhibitor
noroviru
hydroxyl
group
bisulfit
adduct
provid
conveni
site
derivat
yield
ester
carbam
prodrug
enzymemedi
nonenzymat
hydrolysi
convert
prodrug
aldehyd
bisulfit
adduct
subsequ
revert
precursor
aldehyd
macrocycl
compound
frequent
display
good
pharmacolog
activ
select
enhanc
permeabl
improv
metabol
stabil
consequ
intens
interest
macrocycl
inhibitor
util
drug
discoveri
develop
design
rational
macrocycl
noroviru
inhibitor
entail
follow
consider
firstli
proteas
known
recogn
ligand
conform
therefor
macrocycl
effect
way
preorgan
peptidyl
transitionst
mimic
conform
suitabl
bind
activ
site
proteas
invari
increas
affin
reduc
loss
entropi
upon
inhibitor
bind
secondli
macrocycl
increas
cellular
permeabl
particularli
design
includ
format
intramolecular
hydrogen
bond
well
proteolyt
stabil
thu
macrocycl
gener
enhanc
druglik
characterist
noroviru
plastic
subsit
allow
design
macrocycl
inhibitor
tether
gln
side
chain
residu
side
chain
base
consider
group
synthes
evalu
first
time
seri
novel
class
macrocycl
compound
antivir
effect
norovirus
figur
includ
triazolebas
macrocycl
inhibitor
oxadiazolebas
macrocycl
inhibitor
macrocycl
inhibitor
incorpor
methylen
linker
figur
nonoptim
macrocycl
compound
found
cell
permeabl
display
moder
inhibitori
activ
nv
viral
replic
cell
rang
nv
replicon
harbor
cell
xray
cocrystal
macrocycl
compound
show
compound
number
hydrogen
bond
nv
inhibitor
decreas
comparison
nonmacrocycl
dipeptidyl
compound
aris
major
structur
reorgan
activ
site
figur
pharmacolog
activ
cellular
permeabl
found
depend
interplay
sever
factor
includ
ring
size
type
linker
structur
determin
group
report
first
time
rupintrivir
enteroviru
proteas
inhibitor
also
effect
noroviru
replic
rupintrivir
tripeptidyl
compound
possess
ester
michael
acceptor
warhead
inactiv
noroviru
irrevers
presum
michael
addit
reaction
sever
tripeptidyl
compound
synthes
glutamin
surrog
posit
effect
noroviru
fluoresc
reson
energi
transfer
fret
cellbas
assay
examin
sar
studi
tripeptidyl
seri
compound
show
like
dipeptidyl
inhibitor
cyclohexyl
alanin
posit
increas
potenc
addit
cellular
permeabl
tripeptidyl
compound
depend
natur
residu
posit
compound
hydrophob
residu
naphthyl
alanin
phe
highli
effect
fret
cellbas
assay
best
compound
replicon
harbor
cell
detail
structur
efficaci
tripeptidyl
compound
seri
report
prior
report
similar
tripeptidyl
compound
acycl
amid
lactam
ring
posit
synthes
evalu
antinoroviru
effect
howev
efficaci
lower
enzym
cellbas
assay
felin
infecti
periton
fip
caus
virul
felin
coronaviru
highli
fatal
fatal
cat
fip
granulomat
vascul
granuloma
lesion
compos
mainli
virusinfect
macrophag
found
variou
organ
lead
clinic
sign
may
includ
characterist
bodili
effus
absolut
lymphopenia
promin
featur
experiment
natur
infect
fip
associ
massiv
apoptosi
uninfect
tcell
appear
preced
clinic
sign
typic
fip
due
conserv
proteas
picornavirus
calicivirus
picornavirus
dipeptidyl
tripeptidyl
compound
seri
also
effect
multipl
virus
famili
sinc
bisulfit
adduct
correspond
aldehyd
potent
inhibit
felin
infecti
periton
viru
fipv
cell
cultur
fipv
strain
determin
efficaci
fip
cat
proofofconcept
studi
use
experimentallyinfect
pathogenfre
spf
cat
clientown
cat
natur
infect
fipv
studi
demonstr
well
toler
anim
continu
treatment
first
time
druglik
smallmolecul
inhibitor
molecul
coronavirus
norovirus
serv
potenti
antivir
therapeut
proteas
proven
therapeut
target
antivir
group
work
develop
proteas
inhibitor
norovirus
past
sever
year
ration
design
transitionst
inhibitor
consist
dipeptidyl
tripeptidyl
macrocycl
compound
highli
effect
inhibitor
valid
xray
cocrystal
enzym
cellbas
assay
well
anim
model
gener
optim
campaign
util
initi
hit
compound
find
warrant
develop
cite
seri
compound
beyond
preclin
test
